Dr Toni Choueiri, from the Dana-Farber Cancer Institute in Boston, USA, discusses the role of cabozantinib (Cabometyx) for patients with renal cell carcinoma (RCC).

There is potential for cabozantinib to be an option for the first-line treatment of patients with RCC, states Choueiri. In the results of the phase II CABOSUN trial, cabozantinib showed superiority in progression-free survival (PFS).

See the video interview from OncLive here